One trial (NCT01150097) currently underway is investigating the effects of everolimus with CNI elimination/reduction on renal function in de novo liver transplant recipients and will also provide more information on the role of mTOR inhibitors on posttransplant diabetes and hypertension. The gene discussed is MTOR; the disease is hypertensive disorder.